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NEWS AND PERSPECTIVES
Statistics from the Joint United Nations Pro-
gramme on HIV/AIDS (www.unaids.org) show that
33 million individuals worldwide are living with
acquired immune deficiency syndrome (AIDS).
More than 2 million people die from AIDS and
2.7 million others become newly infected with
human immunodeficiency virus type 1 (HIV-1)
each year. HIV/AIDS impacts all parts of the
globe including China and Taiwan.1–3
Progress on AIDS therapy has been remark-
able. Currently, there are more than 24 approved
antiviral drugs/combinations for treating HIV-1
infection.4 However, the World Health Organiz-
ation has found that among the 30 million people
with HIV-1 infection in low- and middle-income
countries, only 4 million of them had access to
anti-retroviral drugs as of the end of 2008. If global
control of HIV-1 infection is to be achieved, it
will require further advances on all fronts and
none would be more contributory than the suc-
cessful development of an effective prophylactic
vaccine.
Regrettably, several large-scale HIV-1 vaccine
trials have failed to demonstrate efficacy.5–8 These
failures raise the specter that a prophylactic vac-
cine against this highly mutable retrovirus might
be difficult, if not impossible, to achieve. Never-
theless, a sense of cautious optimism in some
circles has been kindled recently by the results
from the latest HIV-1 vaccination trial conducted
with ALVAC and AIDSVAX in Thailand.9 How
justified is this optimism?
The Thai study employed a “prime-boost”
strategy using four inoculations with ALVAC-HIV
(vCP1521), a live-attenuated canary pox virus en-
gineered to contain subtype E HIV-1 glycoprotein
(gp) 120 (92TH023) linked to the transmembrane
anchoring portion of gp41 (from HIV LAI) and
gag and protease (from HIV-1 LAI). ALVAC-HIV
was administered at baseline, week 4, week 12
and week 24. Additionally, two booster shots 
for AIDSVAX B/E, a bivalent subunit vaccine pre-
pared by combining recombinant gp120 from
subtype B. HIV-1 MN and subtype E HIV-1A244
in alum adjuvant, were given at week 12 and
week 24. The study enrolled 16,402 healthy men
and women between the ages of 18 and 30 years 
in a community-based, randomized multicenter,
double-blind, placebo-controlled efficacy trial.
The participants were monitored for the co-
primary endpoints of HIV-1 infection and early
HIV-1 viremia at the end of the 6-month vaccina-
tion protocol and every 6 months thereafter for 
3 years.
Three analyses of the results from the Thai trial
revealed the following.9 In the intention-to-treat
(ITT) analysis which contains all 16,402 enrollees,
there were 76 HIV-1 infections in the placebo
group and 56 infections in the vaccine group, 
a vaccine efficacy of 26.4%. In a modified ITT
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(mITT) analysis, which excludes seven enrollees
who were found during the study to have been
infected with HIV at baseline, there were 74 in-
fections in the placebo group and 51 infections
in the vaccine group, a vaccine efficacy of 31.2%.
Finally, in the per protocol (PP) analysis, which
excludes almost 4000 enrollees who did not fully
comply and follow the study protocol to the let-
ter, there were 50 infections in the placebo group
and 36 infections in the vaccine group, a vaccine
efficacy of 26.2%. Based on these results, the 
p values for 95% confidence interval for ITT, mITT,
and PP are 0.08, 0.04, and 0.16 respectively. These
p values indicate that there was an 8%, 4%, and
16% probability that the ITT, mITT, and PP 
vaccine efficacy results were due to chance. Thus,
amongst the three analyses, only the p value from
the mITT analysis is less than 0.05, generally 
accepted as a cutoff for statistical significance.
How should one interpret the above numbers?
The answer to this question is not entirely clear.
In the literature, it has been stated that the ITT/
mITT analysis is conservative for demonstrating
differences,10 while PP analysis tends to provide,
on average, higher estimates of effect than the
ITT/mITT analysis.11,12 Thus, the conventional
wisdom has been that the ITT/mITT analysis is
likely to estimate a smaller absolute treatment
difference than the PP analysis.11,12 Because the
PP analysis measures the “pure” treatment effect
in the set of patients who comply with therapy
and have no other complicating factors,10 this can
often give a better efficacy result than that seen
from an ITT/mITT analysis. Nonetheless, a con-
cern with the PP analysis is that it might intro-
duce bias related to excluding participants who
fail to comply fully with the study protocol.13
Clearly, the simplest interpretation of a clinical
trial would be if the ITT, mITT, and PP analyses
were all fully concordant. When the analyses do
not closely agree, Porta et al have cautioned that
“a clinical trial cannot rest on the single reporting
of either the ITT or PP approach alone”.14 While
the Thai study provides a glimmer of hope that
this HIV-1 vaccination trial may have provided
modestly beneficial results, a careful parsing of
the difference in statistical significance between
the mITT and PP analyses by expert biostatisti-
cians is warranted. This is all more important
since the study showed no significant difference
in the mean viral load amongst those found to
have acquired HIV-1 infection in the vaccine
group versus those in the placebo group.9
The recent Thai HIV-1 vaccine trial is a step in
the right direction. Further analyses of the partic-
ipants’ blood samples may yet reveal correlates
of immune protection against HIV-1. Based on
the reported results, the Thai ALVAC-AIDSVAX
protocol is not the “holy grail” of HIV-1 vaccines
that researchers have been seeking. Thus, para-
phrasing the words of the poet Robert Frost, while
further vaccine research is one road that must be
taken, there are many more “miles to go” before
we can sleep.15 The other road of basic HIV-1 re-
search directed towards understanding viral patho-
genesis and cellular restriction factors also needs
to be traveled.16,17
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